Lactulose: the Advantages and Place of the Drug in Clinical Recommendations

D. S. Bordin, L.Kh. Indeikina, E. Vinnitskaya, M.A. Danilov, E. Sabelnikova
{"title":"Lactulose: the Advantages and Place of the Drug in Clinical Recommendations","authors":"D. S. Bordin, L.Kh. Indeikina, E. Vinnitskaya, M.A. Danilov, E. Sabelnikova","doi":"10.33978/2307-3586-2023-19-35-42-49","DOIUrl":null,"url":null,"abstract":"Lactulose is a disaccharide derived from lactose milk sugar using β-galactosidase or epimerase and consisting of fructose and galactose. The first mention of lactulose dates back to 1929, but clinical interest in this drug appeared much later. In 1957, Petuely discovered that the use of lactulose increased the number of fecal bacteria of the genus Bifidobacterium in infants. The features of the drug are described, the mechanism of action of which allows reproducing both laxative and prebiotic effects. The restoration of intestinal microbiocenosis is associated with the improvement in the course of diseases (constipation, hepatic encephalopathy) and the quality of patients’ life. Due to the possibility of use in different age periods, especially in sensitive categories, children, pregnant and elderly patients, as well as the duration and safety of its use, lactulose has advantages in comparison with other drugs. Considered the principles of lactulose use in patients with chronic functional constipation and liver diseases reflected in clinical recommendations","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"77 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Effective Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33978/2307-3586-2023-19-35-42-49","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Lactulose is a disaccharide derived from lactose milk sugar using β-galactosidase or epimerase and consisting of fructose and galactose. The first mention of lactulose dates back to 1929, but clinical interest in this drug appeared much later. In 1957, Petuely discovered that the use of lactulose increased the number of fecal bacteria of the genus Bifidobacterium in infants. The features of the drug are described, the mechanism of action of which allows reproducing both laxative and prebiotic effects. The restoration of intestinal microbiocenosis is associated with the improvement in the course of diseases (constipation, hepatic encephalopathy) and the quality of patients’ life. Due to the possibility of use in different age periods, especially in sensitive categories, children, pregnant and elderly patients, as well as the duration and safety of its use, lactulose has advantages in comparison with other drugs. Considered the principles of lactulose use in patients with chronic functional constipation and liver diseases reflected in clinical recommendations
乳果糖:该药物的优势及其在临床建议中的地位
乳果糖是一种由果糖和半乳糖组成的双糖,通过β-半乳糖苷酶或表聚合酶从乳糖牛奶糖中提取。最早提及乳果糖可追溯到 1929 年,但临床上对这种药物的兴趣却出现得更晚。1957 年,Petuely 发现使用乳果糖可以增加婴儿粪便中双歧杆菌属细菌的数量。该药物的作用机制使其同时具有润肠通便和益生菌的作用。肠道微生物群的恢复与病程(便秘、肝性脑病)的改善和患者生活质量的提高有关。由于乳果糖可用于不同年龄段,尤其是敏感人群、儿童、孕妇和老年患者,而且使用时间长、安全性高,因此与其他药物相比具有优势。考虑到临床建议中反映的慢性功能性便秘和肝病患者使用乳果糖的原则
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信